Clinical Psychopharmacology and Neuroscience 2011 Aug; 9(2): 54-66
Panel of Genetic Variations as a Potential Non-invasive Biomarker for Early Diagnosis of Alzheimer’s Disease
Suk Ling Ma1,2, Linda Chiu Wa Lam2
1Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA, 2Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
Alzheimer’s disease (AD) is the most prevalent form of dementia. Biomarkers such as levels of amyloid beta (Aβ) in cerebrospinal fluid and ApoE genotyping were suggested for the diagnosis of AD, however, the result is either non-conclusive or with invasive procedure. Genome-wide association studies (GWASs) for AD suggested single nucleotide polymorphisms (SNPs) in many genes are associated with the risk of AD, but each only contributed with small effect to the disease. By incorporating a panel of established genetic susceptibility factors, the risk of an individual in getting AD could be better estimated. Further research will be required to reveal if adding to the current well-developed clinical diagnosis protocol, the accuracy and specificity of diagnosis of AD would be greatly improved and if this might also be beneficial in identifying pre-symptomatic AD patients for early diagnosis and intervention of the disease.
Clinical Psychopharmacology and Neuroscience 2011 Aug; 9(2): 54-66
Keyword : Alzheimer disease; Genetics; Biomarkers; Diagnosis.
2010 © Copyright The Korean College of Neuropsychopharmacology. All Rights Reserved.
RN. 1003 Life Officetel, 40, 63-ro, Yeongdeungpo-gu, Seoul 150-731, Korea
Tel) +82-2-784-2742   Fax) +82-2-784-5542   E-mail)   Powered by, Ltd